Table of Contents Author Guidelines Submit a Manuscript
PPAR Research
Volume 2008 (2008), Article ID 247379, 8 pages
http://dx.doi.org/10.1155/2008/247379
Review Article

PPAR 𝛾 and PPAR 𝛿 as Modulators of Neoplasia and Cell Fate

Department of Oncology and Lombardi Comprehensive Cancer Center, School of Medicine, Georgetown University, 3970 Reservoir Road, NW, Washington, DC 20007, USA

Received 9 May 2008; Accepted 22 May 2008

Academic Editor: Dipak Panigrahy

Copyright © 2008 Robert I. Glazer et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Auwerx, “Nuclear receptors I. PPARγ in the gastrointestinal tract: gain or pain?” American Journal of Physiology: Gastrointestinal and Liver Physiology, vol. 282, no. 4, pp. G581–G585, 2002. View at Publisher · View at Google Scholar
  2. H. P. Koeffler, “Peroxisome proliferator-activated receptor γ and cancers,” Clinical Cancer Research, vol. 9, no. 1, pp. 1–9, 2003. View at Google Scholar
  3. L. Michalik, B. Desvergne, and W. Wahli, “Peroxisome-proliferator-activated receptors and cancers: complex stories,” Nature Reviews Cancer, vol. 4, no. 1, pp. 61–70, 2004. View at Publisher · View at Google Scholar
  4. J. P. Berger, T. E. Akiyama, and P. T. Meinke, “PPARs: therapeutic targets for metabolic disease,” Trends in Pharmacological Sciences, vol. 26, no. 5, pp. 244–251, 2005. View at Publisher · View at Google Scholar
  5. R. M. Evans, G. D. Barish, and Y.-X. Wang, “PPARs and the complex journey to obesity,” Nature Medicine, vol. 10, no. 4, pp. 355–361, 2004. View at Publisher · View at Google Scholar
  6. M. Lehrke and M. A. Lazar, “The many faces of PPARγ,” Cell, vol. 123, no. 6, pp. 993–999, 2005. View at Publisher · View at Google Scholar
  7. C. Grommes, G. E. Landreth, and M. T. Heneka, “Antineoplastic effects of peroxisome proliferator-activated receptor γ agonists,” The Lancet Oncology, vol. 5, no. 7, pp. 419–429, 2004. View at Publisher · View at Google Scholar
  8. L. Kopelovich, J. R. Fay, R. I. Glazer, and J. A. Crowell, “Peroxisome proliferator-activated receptor modulators as potential chemopreventive agents,” Molecular Cancer Therapeutics, vol. 1, no. 5, pp. 357–363, 2002. View at Google Scholar
  9. J. Berger and J. A. Wagner, “Physiological and therapeutic roles of peroxisome proliferator-activated receptors,” Diabetes Technology and Therapeutics, vol. 4, no. 2, pp. 163–174, 2002. View at Publisher · View at Google Scholar
  10. J. M. Olefsky and A. R. Saltiel, “PPARγ and the treatment of insulin resistance,” Trends in Endocrinology and Metabolism, vol. 11, no. 9, pp. 362–368, 2000. View at Publisher · View at Google Scholar
  11. T. M. Willson, P. J. Brown, D. D. Sternbach, and B. R. Henke, “The PPARs: from orphan receptors to drug discovery,” Journal of Medicinal Chemistry, vol. 43, no. 4, pp. 527–550, 2000. View at Publisher · View at Google Scholar
  12. C. Knouff and J. Auwerx, “Peroxisome proliferator-activated receptor-γ calls for activation in moderation: lessons from genetics and pharmacology,” Endocrine Reviews, vol. 25, no. 6, pp. 899–918, 2004. View at Publisher · View at Google Scholar
  13. P. Sarraf, E. Mueller, W. M. Smith et al., “Loss-of-function mutations in PPAR? associated with human colon cancer,” Molecular Cell, vol. 3, no. 6, pp. 799–804, 1999. View at Publisher · View at Google Scholar
  14. S. S. Deeb, L. Fajas, M. Nemoto et al., “A Pro12Ala substitution in PPAR?2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity,” Nature Genetics, vol. 20, no. 3, pp. 284–287, 1998. View at Publisher · View at Google Scholar
  15. M. Ristow, D. Müller-Wieland, A. Pfeiffer, W. Krone, and C. R. Kahn, “Obesity associated with a mutation in a genetic regulator of adipocyte differentiation,” The New England Journal of Medicine, vol. 339, no. 14, pp. 953–959, 1998. View at Publisher · View at Google Scholar
  16. D. Shao and M. A. Lazar, “Peroxisome proliferator activated receptor γ, CCAAT/enhancer-binding protein α, and cell cycle status regulate the commitment to adipocyte differentiation,” Journal of Biological Chemistry, vol. 272, no. 34, pp. 21473–21478, 1997. View at Publisher · View at Google Scholar
  17. T. Ikezoe, C. W. Miller, S. Kawano et al., “Mutational analysis of the peroxisome proliferator-activated receptor ? in human malignancies,” Cancer Research, vol. 61, no. 13, pp. 5307–5310, 2001. View at Google Scholar
  18. T. G. Kroll, P. Sarraf, L. Pecciarini et al., “PAX8-PPAR?1 fusion in oncogene human thyroid carcinoma,” Science, vol. 289, no. 5483, pp. 1357–1360, 2000. View at Publisher · View at Google Scholar
  19. Y. Yin, H. Yuan, C. Wang et al., “3-phosphoinositide-dependent protein kinase-1 activates the peroxisome proliferator-activated receptor- and promotes adipocyte differentiation,” Molecular Endocrinology, vol. 20, no. 2, pp. 268–278, 2006. View at Publisher · View at Google Scholar
  20. T. Foukakis, A. Y. M. Au, G. Wallin et al., “The Ras effector NORE1A is suppressed in follicular thyroid carcinomas with a PAX8-PPAR? fusion,” The Journal of Clinical Endocrinology & Metabolism, vol. 91, no. 3, pp. 1143–1149, 2006. View at Publisher · View at Google Scholar
  21. A. Moshnikova, J. Frye, J. W. Shay, J. D. Minna, and A. V. Khokhlatchev, “The growth and tumor suppressor NORE1A is a cytoskeletal protein that suppresses growth by inhibition of the ERK pathway,” Journal of Biological Chemistry, vol. 281, no. 12, pp. 8143–8152, 2006. View at Publisher · View at Google Scholar
  22. L. Patel, I. Pass, P. Coxon, C. P. Downes, S. A. Smith, and C. H. Macphee, “Tumor suppressor and anti-inflammatory actions of PPARγ agonists are mediated via upregulation of PTEN,” Current Biology, vol. 11, no. 10, pp. 764–768, 2001. View at Publisher · View at Google Scholar
  23. M. Pignatelli, C. Cocca, A. Santos, and A. Perez-Castillo, “Enhancement of BRCA1 gene expression by the peroxisome proliferator-activated receptor γ in the MCF-7 breast cancer cell line,” Oncogene, vol. 22, no. 35, pp. 5446–5450, 2003. View at Publisher · View at Google Scholar
  24. Y. Yin, H. Yuan, S. Mueller, L. Kopelovich, and R. I. Glazer, “Peroxisome proliferator-activated receptor γ is a regulator of mammary stem and progenitor cell self-renewal and estrogen-dependent tumor specification,” in Proceedings of the American Association for Cancer Research, Los Angeles, Calif, USA, April 2007.
  25. S. Liu, C. Ginestier, E. Charafe-Jauffret et al., “BRCA1 regulates human mammary stem/progenitor cell fate,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 5, pp. 1680–1685, 2008. View at Publisher · View at Google Scholar
  26. A. D. Cristofano, B. Pesce, C. Cordon-Cardo, and P. P. Pandolfi, “Pten is essential for embryonic development and tumour suppression,” Nature Genetics, vol. 19, no. 4, pp. 348–355, 1998. View at Publisher · View at Google Scholar
  27. S. Wang, A. J. Garcia, M. Wu, D. A. Lawson, O. N. Witte, and H. Wu, “Pten deletion leads to the expansion of a prostatic stem/progenitor cell subpopulation and tumor initiation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 5, pp. 1480–1485, 2006. View at Publisher · View at Google Scholar
  28. M. Groszer, R. Erickson, D. D. Scripture-Adams et al., “Negative regulation of neural stem/progenitor cell proliferation by the Pten tumor suppressor gene in vivo,” Science, vol. 294, no. 5549, pp. 2186–2189, 2001. View at Publisher · View at Google Scholar
  29. J. DiRenzo, M. Söderström, R. Kurokawa et al., “Peroxisome proliferator-activated receptors and retinoic acid receptors differentially control the interactions of retinoid X receptor heterodimers with ligands, coactivators, and corepressors,” Molecular and Cellular Biology, vol. 17, no. 4, pp. 2166–2176, 1997. View at Google Scholar
  30. R. M. Lavinsky, K. Jepsen, T. Heinzel et al., “Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 6, pp. 2920–2925, 1998. View at Publisher · View at Google Scholar
  31. R. T. Nolte, G. B. Wisely, S. Westin et al., “Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-?,” Nature, vol. 395, no. 6698, pp. 137–143, 1998. View at Publisher · View at Google Scholar
  32. Y. Shang, X. Hu, J. DiRenzo, M. A. Lazar, and M. Brown, “Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription,” Cell, vol. 103, no. 6, pp. 843–852, 2000. View at Publisher · View at Google Scholar
  33. K. D. Houston, J. A. Copland, R. R. Broaddus, M. M. Gottardis, S. M. Fischer, and C. L. Walker, “Inhibition of proliferation and estrogen receptor signaling by peroxisome proliferator-activated receptor γ ligands in uterine leiomyoma,” Cancer Research, vol. 63, no. 6, pp. 1221–1227, 2003. View at Google Scholar
  34. H. Keller, F. Givel, M. Perroud, and W. Wahli, “Signaling cross-talk between peroxisome proliferator-activated receptor/retinoid X receptor and estrogen receptor through estrogen response elements,” Molecular Endocrinology, vol. 9, no. 7, pp. 794–804, 1995. View at Publisher · View at Google Scholar
  35. Y. Liu, H. Gao, T. T. Marstrand et al., “The genome landscape of ERa- and ERß-binding DNA regions,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 7, pp. 2604–2609, 2008. View at Publisher · View at Google Scholar
  36. D. Bonofiglio, S. Gabriele, S. Aquila et al., “Estrogen receptor a binds to peroxisome proliferator-activated receptor response element and negatively interferes with peroxisome proliferator-activated receptor ? signaling in breast cancer cells,” Clinical Cancer Research, vol. 11, no. 17, pp. 6139–6147, 2005. View at Publisher · View at Google Scholar
  37. C. Qin, R. Burghardt, R. Smith, M. Wormke, J. Stewart, and S. Safe, “Peroxisome proliferator-activated receptor γ agonists induce proteasome-dependent degradation of cyclin D1 and estrogen receptor α in MCF-7 breast cancer cells,” Cancer Research, vol. 63, no. 5, pp. 958–964, 2003. View at Google Scholar
  38. T. Yanase, Y.-M. Mu, Y. Nishi et al., “Regulation of aromatase by nuclear receptors,” Journal of Steroid Biochemistry and Molecular Biology, vol. 79, no. 1–5, pp. 187–192, 2001. View at Publisher · View at Google Scholar
  39. W. Fan, T. Yanase, H. Morinaga et al., “Activation of peroxisome proliferator-activated receptor-? and retinoid X receptor inhibits aromatase transcription via nuclear factor-?B,” Endocrinology, vol. 146, no. 1, pp. 85–92, 2005. View at Publisher · View at Google Scholar
  40. E. Saez, J. Rosenfeld, A. Livolsi et al., “PPAR? signaling exacerbates mammary gland tumor development,” Genes & Development, vol. 18, no. 5, pp. 528–540, 2004. View at Publisher · View at Google Scholar
  41. Y. Li and M. A. Lazar, “Differential gene regulation by PPARγ agonist and constitutively active PPARγ2,” Molecular Endocrinology, vol. 16, no. 5, pp. 1040–1048, 2002. View at Publisher · View at Google Scholar
  42. E. Saez, P. Olson, and R. M. Evans, “Genetic deficiency in Pparg does not alter development of experimental prostate cancer,” Nature Medicine, vol. 9, no. 10, pp. 1265–1266, 2003. View at Publisher · View at Google Scholar
  43. A.-M. Lefebvre, I. Chen, P. Desreumaux et al., “Activation of the peroxisome proliferator-activated receptor ? promotes the development of colon tumors in C57BL/6J-APCmin/+ mice,” Nature Medicine, vol. 4, no. 9, pp. 1053–1057, 1998. View at Publisher · View at Google Scholar
  44. E. Saez, P. Tontonoz, M. C. Nelson et al., “Activators of the nuclear receptor PPAR? enhance colon polyp formation,” Nature Medicine, vol. 4, no. 9, pp. 1058–1061, 1998. View at Publisher · View at Google Scholar
  45. M. V. Pino, M. F. Kelley, and Z. Jayyosi, “Promotion of colon tumors in C57BL/6J-APCmin/+ mice by thiazolidinedione PPARγ agonists and a structurally unrelated PPARγ agonist,” Toxicologic Pathology, vol. 32, no. 1, pp. 58–63, 2004. View at Publisher · View at Google Scholar
  46. G. D. Girnun, W. M. Smith, S. Drori et al., “APC-dependent suppression of colon carcinogenesis by PPAR?,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 21, pp. 13771–13776, 2002. View at Publisher · View at Google Scholar
  47. D. Lu, H. B. Cottam, M. Corr, and D. A. Carson, “Repression of β-catenin function in malignant cells by nonsteroidal antiinflammatory drugs,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 51, pp. 18567–18571, 2005. View at Publisher · View at Google Scholar
  48. J. A. Brockman, R. A. Gupta, and R. N. Dubois, “Activation of PPARγ leads to inhibition of anchorage-independent growth of human colorectal cancer cells,” Gastroenterology, vol. 115, no. 5, pp. 1049–1055, 1998. View at Publisher · View at Google Scholar
  49. P. Sarraf, E. Mueller, D. Jones et al., “Differentiation and reversal of malignant changes in colon cancer through PPAR?,” Nature Medicine, vol. 4, no. 9, pp. 1046–1052, 1998. View at Publisher · View at Google Scholar
  50. G. M. Pighetti, W. Novosad, C. Nicholson et al., “Therapeutic treatment of DMBA-induced mammary tumors with PPAR ligands,” Anticancer Research, vol. 21, no. 2A, pp. 825–829, 2001. View at Google Scholar
  51. N. Suh, Y. Wang, C. R. Williams et al., “A new ligand for the peroxisome proliferator-activated receptor-? (PPAR-?), GW7845, inhibits rat mammary carcinogenesis,” Cancer Research, vol. 59, no. 22, pp. 5671–5673, 1999. View at Google Scholar
  52. Y. Yin, R. G. Russell, L. E. Dettin et al., “Peroxisome proliferator-activated receptor d and ? agonists differentially alter tumor differentiation and progression during mammary carcinogenesis,” Cancer Research, vol. 65, no. 9, pp. 3950–3957, 2005. View at Publisher · View at Google Scholar
  53. E. Elstner, C. Müller, K. Koshizuka et al., “Ligands for peroxisome proliferator-activated receptor? and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 15, pp. 8806–8811, 1998. View at Publisher · View at Google Scholar
  54. S. Kitamura, Y. Miyazaki, S. Hiraoka et al., “PPAR? agonists inhibit cell growth and suppress the expression of cyclin D1 and EGF-like growth factors in ras-transformed rat intestinal epithelial cells,” International Journal of Cancer, vol. 94, no. 3, pp. 335–342, 2001. View at Publisher · View at Google Scholar
  55. W. Motomura, T. Okumura, N. Takahashi, T. Obara, and Y. Kohgo, “Activation of peroxisome proliferator-activated receptor γ by troglitazone inhibits cell growth through the increase of p27Kip1 in human pancreatic carcinoma cells,” Cancer Research, vol. 60, no. 19, pp. 5558–5564, 2000. View at Google Scholar
  56. A. Itami, G. Watanabe, Y. Shimada et al., “Ligands for peroxisome proliferator-activated receptor ? inhibit growth of pancreatic cancers both in vitro and in vivo,” International Journal of Cancer, vol. 94, no. 3, pp. 370–376, 2001. View at Publisher · View at Google Scholar
  57. H. Koga, S. Sakisaka, M. Harada et al., “Involvement of p21WAF1/Cip1, p27Kip1, and p18INK4c in troglitazone-induced cell-cycle arrest in human hepatoma cell lines,” Hepatology, vol. 33, no. 5, pp. 1087–1097, 2001. View at Publisher · View at Google Scholar
  58. J. A. Copland, L. A. Marlow, S. Kurakata et al., “Novel high-affinity PPAR? agonist alone and in combination with paclitaxel inhibits human anaplastic thyroid carcinoma tumor growth via p21WAF1/CIP1,” Oncogene, vol. 25, no. 16, pp. 2304–2317, 2006. View at Publisher · View at Google Scholar
  59. C.-W. Shiau, C.-C. Yang, S. K. Kulp et al., “Thiazolidenediones mediate apoptosis in prostate cancer cells in part through inhibition of Bcl-xL/Bcl-2 functions independently of PPAR?,” Cancer Research, vol. 65, no. 4, pp. 1561–1569, 2005. View at Publisher · View at Google Scholar
  60. C.-H. Lee, A. Chawla, N. Urbiztondo, D. Liao, W. A. Boisvert, and R. M. Evans, “Transcriptional repression of atherogenic inflammation: modulation by PPARδ,” Science, vol. 302, no. 5644, pp. 453–457, 2003. View at Publisher · View at Google Scholar
  61. J. B. Hansen, H. Zhang, T. H. Rasmussen, R. K. Petersen, E. N. Flindt, and K. Kristiansen, “Peroxisome proliferator-activated receptor δ (PPARδ)-mediated regulation of preadipocyte proliferation and gene expression is dependent on cAMP signaling,” Journal of Biological Chemistry, vol. 276, no. 5, pp. 3175–3182, 2001. View at Publisher · View at Google Scholar
  62. D. Holst, S. Luquet, K. Kristiansen, and P. A. Grimaldi, “Roles of peroxisome proliferator-activated receptors delta and gamma in myoblast transdifferentiation,” Experimental Cell Research, vol. 288, no. 1, pp. 168–176, 2003. View at Publisher · View at Google Scholar
  63. P. Pelton, “GW-501516 GlaxoSmithKline/ligand,” Current Opinion in Investigational Drugs, vol. 7, no. 4, pp. 360–370, 2006. View at Google Scholar
  64. J. M. Peters, S. S. T. Lee, W. Li et al., “Growths, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor ß(d),” Molecular and Cellular Biology, vol. 20, no. 14, pp. 5119–5128, 2000. View at Publisher · View at Google Scholar
  65. Y. Barak, D. Liao, W. He et al., “Effects of peroxisome proliferator-activated receptor d on placentation, adiposity, and colorectal cancer,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 1, pp. 303–308, 2002. View at Publisher · View at Google Scholar
  66. L. Jow and R. Mukherjee, “The human peroxisome proliferator-activated receptor (PPAR) subtype NUC1 represses the activation of hPPARα and thyroid hormone receptors,” Journal of Biological Chemistry, vol. 270, no. 8, pp. 3836–3840, 1995. View at Publisher · View at Google Scholar
  67. Y. Shi, M. Hon, and R. M. Evans, “The peroxisome proliferator-activated receptor δ, an integrator of transcriptional repression and nuclear receptor signaling,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 5, pp. 2613–2618, 2002. View at Publisher · View at Google Scholar
  68. K. M. Suchanek, F. J. May, W. J. Lee, N. A. Holman, and S. J. Roberts-Thomson, “Peroxisome proliferator-activated receptor β expression in human breast epithelial cell lines of tumorigenic and non-tumorigenic origin,” International Journal of Biochemistry and Cell Biology, vol. 34, no. 9, pp. 1051–1058, 2002. View at Publisher · View at Google Scholar
  69. J. Shao, H. Sheng, and R. N. DuBois, “Peroxisome proliferator-activated receptors modulate K-Ras-mediated transformation of intestinal epithelial cells,” Cancer Research, vol. 62, no. 11, pp. 3282–3288, 2002. View at Google Scholar
  70. J. Zhang, M. Fu, X. Zhu et al., “Peroxisome proliferator-activated receptor d is up-regulated during vascular lesion formation and promotes post-confluent cell proliferation in vascular smooth muscle cells,” Journal of Biological Chemistry, vol. 277, no. 13, pp. 11505–11512, 2002. View at Publisher · View at Google Scholar
  71. R. L. Stephen, M. C. U. Gustafsson, M. Jarvis et al., “Activation of peroxisome proliferator-activated receptor d stimulates the proliferation of human breast and prostate cancer cell lines,” Cancer Research, vol. 64, no. 9, pp. 3162–3170, 2004. View at Publisher · View at Google Scholar
  72. N. Di-Poï, N. S. Tan, L. Michalik, W. Wahli, and B. Desvergne, “Antiapoptotic role of PPARβ in keratinocytes via transcriptional control of the Akt1 signaling pathway,” Molecular Cell, vol. 10, no. 4, pp. 721–733, 2002. View at Publisher · View at Google Scholar
  73. N. Di-Poï, L. Michalik, N. S. Tan, B. Desvergne, and W. Wahli, “The anti-apoptotic role of PPARβ contributes to efficient skin wound healing,” Journal of Steroid Biochemistry and Molecular Biology, vol. 85, no. 2–5, pp. 257–265, 2003. View at Publisher · View at Google Scholar
  74. M. H. Fenner and E. Elstner, “Peroxisome proliferator-activated receptor-γ ligands for the treatment of breast cancer,” Expert Opinion on Investigational Drugs, vol. 14, no. 6, pp. 557–568, 2005. View at Publisher · View at Google Scholar
  75. T.-C. He, T. A. Chan, B. Vogelstein, and K. W. Kinzler, “PPARδ is an APC-regulated target of nonsteroidal anti-inflammatory drugs,” Cell, vol. 99, no. 3, pp. 335–345, 1999. View at Publisher · View at Google Scholar
  76. B. H. Park, B. Vogelstein, and K. W. Kinzler, “Genetic disruption of PPARδ decreases the tumorigenicity of human colon cancer cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 5, pp. 2598–2603, 2001. View at Publisher · View at Google Scholar
  77. R. A. Gupta, D. Wang, S. Katkuri, H. Wang, S. K. Dey, and R. N. DuBois, “Activation of nuclear hormone receptor peroxisome proliferator-activated receptor-δ accelerates intestinal adenoma growth,” Nature Medicine, vol. 10, no. 3, pp. 245–247, 2004. View at Google Scholar
  78. F. S. Harman, C. J. Nicol, H. E. Marin, J. M. Ward, F. J. Gonzalez, and J. M. Peters, “Peroxisome proliferator-activated receptor-δ attenuates colon carcinogenesis,” Nature Medicine, vol. 10, no. 5, pp. 481–483, 2004. View at Publisher · View at Google Scholar
  79. D. J. Kim, I. A. Murray, A. M. Burns, F. J. Gonzalez, G. H. Perdew, and J. M. Peters, “Peroxisome proliferator-activated receptor-β/δ inhibits epidermal cell proliferation by down-regulation of kinase activity,” Journal of Biological Chemistry, vol. 280, no. 10, pp. 9519–9527, 2005. View at Publisher · View at Google Scholar
  80. H. E. Hollingshead, M. G. Borland, A. N. Billin, T. M. Willson, F. J. Gonzalez, and J. M. Peters, “Ligand activation of peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) and inhibition of cyclooxygenase 2 (COX2) attenuate colon carcinogenesis through independent signaling mechanisms,” Carcinogenesis, vol. 29, no. 1, pp. 169–176, 2008. View at Publisher · View at Google Scholar
  81. L. Michalik, B. Desvergne, N. S. Tan et al., “Impaired skin wound healing in peroxisome proliferator-activated receptor (PPAR)a and PPARß mutant mice,” Journal of Cell Biology, vol. 154, no. 4, pp. 799–814, 2001. View at Publisher · View at Google Scholar
  82. R. A. Gupta, J. Tan, W. F. Krause et al., “Prostacyclin-mediated activation of peroxisome proliferator-activated receptor d in colorectal cancer,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 24, pp. 13275–13280, 2000. View at Publisher · View at Google Scholar
  83. W. Strober, I. Fuss, and P. Mannon, “The fundamental basis of inflammatory bowel disease,” Journal of Clinical Investigation, vol. 117, no. 3, pp. 514–521, 2007. View at Publisher · View at Google Scholar
  84. I. Shureiqi, D. Chen, R. Lotan et al., “15-lipoxygenase-1 mediates nonsteroidal anti-inflammatory drug-induced apoptosis independently of cyclooxygenase-2 in colon cancer cells,” Cancer Research, vol. 60, no. 24, pp. 6846–6850, 2000. View at Google Scholar
  85. I. Shureiqi, W. Jiang, X. Zuo et al., “The 15-lipoxygenase-1 product 13-S-hydroxyoctadecadienoic acid down-regulates PPAR-d to induce apoptosis in colorectal cancer cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 17, pp. 9968–9973, 2003. View at Publisher · View at Google Scholar
  86. C. G. Su, X. Wen, S. T. Bailey et al., “A novel therapy for colitis utilizing PPAR-? ligands to inhibit the epithelial inflammatory response,” Journal of Clinical Investigation, vol. 104, no. 4, pp. 383–389, 1999. View at Google Scholar
  87. T.-C. He, A. B. Sparks, C. Rago et al., “Identification of c-MYC as a target of the APC pathway,” Science, vol. 281, no. 5382, pp. 1509–1512, 1998. View at Publisher · View at Google Scholar
  88. Z. Xie, X. Zeng, T. Waldman, and R. I. Glazer, “Transformation of mammary epithelial cells by 3-phosphoinositide-dependent protein kinase-1 activates β-catenin and c-Myc, and down-regulates caveolin-1,” Cancer Research, vol. 63, no. 17, pp. 5370–5375, 2003. View at Google Scholar
  89. X. Zeng, H. Xu, and R. I. Glazer, “Transformation of mammary epithelial cells by 3-phosphoinositide-dependent protein kinase-1 (PDK1) is associated with the induction of protein kinase Cα,” Cancer Research, vol. 62, no. 12, pp. 3538–3543, 2002. View at Google Scholar
  90. H. Lim, R. A. Gupta, W.-G. Ma et al., “Cyclo-oxygenase-2-derived prostacyclin mediates embryo implantation in the mouse via PPARd,” Genes & Development, vol. 13, no. 12, pp. 1561–1574, 1999. View at Google Scholar
  91. B. M. Forman, J. Chen, and R. M. Evans, “Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δ,” Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 9, pp. 4312–4317, 1997. View at Publisher · View at Google Scholar
  92. X. Ma, K.-W. Ling, and E. Dzierzak, “Cloning of the Ly-6A (Sca-1) gene locus and identification of a 3 distal fragment responsible for high-level γ-interferon-induced expression in vitro,” British Journal of Haematology, vol. 114, no. 3, pp. 724–730, 2001. View at Publisher · View at Google Scholar
  93. E. J. Moerman, K. Teng, D. A. Lipschitz, and B. Lecka-Czernik, “Aging activates adipogenic and suppresses osteogenic programs in mesenchymal marrow stroma/stem cells: the role of PPAR-γ2 transcription factor and TGF-β/BMP signaling pathways,” Aging Cell, vol. 3, no. 6, pp. 379–389, 2004. View at Publisher · View at Google Scholar
  94. I. Takada, M. Suzawa, K. Matsumoto, and S. Kato, “Suppression of PPAR transactivation switches cell fate of bone marrow stem cells from adipocytes into osteoblasts,” Annals of the New York Academy of Sciences, vol. 1116, pp. 182–195, 2007. View at Publisher · View at Google Scholar
  95. J. Russo and I. H. Russo, “Influence of differentiation and cell kinetics on the susceptibility of the rat mammary gland to carcinogenesis,” Cancer Research, vol. 40, no. 8, part 1, pp. 2677–2687, 1980. View at Google Scholar
  96. L. Sivaraman, J. Gay, S. G. Hilsenbeck et al., “Effect of selective ablation of proliferating mammary epithelial cells on MNU induced rat mammary tumorigenesis,” Breast Cancer Research and Treatment, vol. 73, no. 1, pp. 75–83, 2002. View at Publisher · View at Google Scholar
  97. D. Medina, F. S. Kittrell, A. Shepard, A. Contreras, J. M. Rosen, and J. Lydon, “Hormone dependence in premalignant mammary progression,” Cancer Research, vol. 63, no. 5, pp. 1067–1072, 2003. View at Google Scholar
  98. J. P. Lydon, G. Ge, F. S. Kittrell, D. Medina, and B. W. O'Malley, “Murine mammary gland carcinogenesis is critically dependent on progesterone receptor function,” Cancer Research, vol. 59, no. 17, pp. 4276–4284, 1999. View at Google Scholar
  99. C. M. Aldaz, Q. Y. Liao, M. LaBate, and D. A. Johnston, “Medroxyprogesterone acetate accelerates the development and increases the incidence of mouse mammary tumors induced by dimethylbenzanthracene,” Carcinogenesis, vol. 17, no. 9, pp. 2069–2072, 1996. View at Publisher · View at Google Scholar
  100. P. Pazos, C. Lanari, R. Meiss, E. H. Charreau, and C. D. Pasqualini, “Mammary carcinogenesis induced by N-methyl-N-nitrosourea (MNU) and medroxyprogesterone acetate (MPA) in BALB/c mice,” Breast Cancer Research and Treatment, vol. 20, no. 2, pp. 133–138, 1992. View at Publisher · View at Google Scholar
  101. Y. Yin, R. Bai, R. G. Russell et al., “Characterization of medroxyprogesterone and DMBA-induced multilineage mammary tumors by gene expression profiling,” Molecular Carcinogenesis, vol. 44, no. 1, pp. 42–50, 2005. View at Publisher · View at Google Scholar
  102. S. Naylor, M. J. Smalley, D. Robertson, B. A. Gusterson, P. A. W. Edwards, and T. C. Dale, “Retroviral expression of Wnt-1 and Wnt-7b produces different effects in mouse mammary epithelium,” Journal of Cell Science, vol. 113, no. 12, pp. 2129–2138, 2000. View at Google Scholar
  103. X. Y. Wang, Y. Yin, H. Yuan, T. Sakamaki, H. Okano, and R. I. Glazer, “Musashi1 modulates mammary progenitor cell expansion through proliferin-mediated activation of the Wnt and Notch pathways,” Molecular and Cellular Biology, vol. 28, no. 11, pp. 3589–3599, 2008. View at Publisher · View at Google Scholar
  104. F. Varnat, B. B. Ten Heggeler, P. Grisel et al., “PPARß/d regulates paneth cell differentiation via controlling the hedgehog signaling pathway,” Gastroenterology, vol. 131, no. 2, pp. 538–553, 2006. View at Publisher · View at Google Scholar
  105. Y. Li, B. Welm, K. Podsypanina et al., “Evidence that transgenes encoding components of the Wnt signaling pathway preferentially induce mammary cancers from progenitor cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 26, pp. 15853–15858, 2003. View at Publisher · View at Google Scholar